ARTICLE | Deals
In third cancer deal, EQRx aims to bring down cost of PD-1, PD-L1 inhibitors
October 28, 2020 1:45 AM UTC
Through its latest deal with CStone, EQRx is looking to bring lower cost PD-1 and PD-L1 inhibitors to market.
EQRx Inc. launched in January with a $200 million series A and a mission to bring innovative products to patients at a fraction of the price of commercial competitors using data science, a slimmed down commercial model and partnerships with payers and others in the healthcare ecosystem. ...